Tempus AI Rises on Merck-Moderna Cancer Trial Breakthrough
Shares of Tempus AI Inc (NASDAQ:TEM) have surged to new heights as investors connect the dots between a landmark clinical trial win and the company's recent acquisition deal. The stock has risen 17.77% to $58.13 at the time of publication, according to Benzinga Pro data.
The rally follows Phase 3 trial results released by Merck & Co Inc and Moderna Inc, which revealed that their INTerpath-001 trial evaluating intismeran autogene, a custom mRNA-based individualized neoantigen therapy paired with Keytruda, significantly improved recurrence-free survival in resected melanoma patients.
The news represents the first successful Phase 3 readout for a custom mRNA-based cancer treatment. Merck and Moderna's partnership utilizes Personalis Inc's advanced genomic tumor-profiling technology to analyze each patient's unique tumor tissue and identify specific neoantigens needed to manufacture custom doses.
Tempus AI, which previously partnered with Personalis to commercialize minimal residual disease tests and agreed to acquire Personalis for $1.5 billion last month, inherits the critical sequencing infrastructure supporting Moderna's therapeutic program just as it passes its biggest regulatory and clinical milestone to date.